# Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.

> **NCT01898364** · PHASE1 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 24 (actual)

## Conditions studied

- Pompe Disease
- Glycogen Storage Disease Type II (GSD II)
- Acid Maltase Deficiency

## Interventions

- **DRUG:** GZ402666

## Key facts

- **NCT ID:** NCT01898364
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08-19
- **Primary completion:** 2015-02-25
- **Final completion:** 2015-02-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2023-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01898364

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01898364, "Safety and Efficacy Evaluation of Repeat neoGAA Dosing in Late Onset Pompe Disease Patients.". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01898364. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*